LabCorp to acquire clinical trials firm Chiltern for $1.2bn
The transaction will help LabCorp create leading expertise in the oncology segment by combining the extensive experience of Covance in late phase with the deep expertise of Chiltern
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.